immunitoAI
immunitoAI is a TechBio company that develops AI-generated novel antibody therapeutics with predefined drug properties using an in-silico design approach. Their AI platform enables intentional de novo antibody design without biological sources, focusing on drug-first antibodies with embedded drug characteristics from inception. The company uses a structure-first AI platform based on neural networks trained on shape complementarity to design precise, target-specific antibodies optimized for affinity and specificity, including for undruggable targets. immunitoAI combines AI technology with in-house biological validation to accelerate antibody drug discovery, aiming to make antibody therapy the norm. They have received multiple awards and recognitions, including from NASSCOM, Karnataka Government, and Google for Startups Accelerator, and have participated in major industry events, demonstrating traction and industry validation.
immunitoAI
immunitoAI is a TechBio company that develops AI-generated novel antibody therapeutics with predefined drug properties using an in-silico design approach. Their AI platform enables intentional de novo antibody design without biological sources, focusing on drug-first antibodies with embedded drug characteristics from inception. The company uses a structure-first AI platform based on neural networks trained on shape complementarity to design precise, target-specific antibodies optimized for affinity and specificity, including for undruggable targets. immunitoAI combines AI technology with in-house biological validation to accelerate antibody drug discovery, aiming to make antibody therapy the norm. They have received multiple awards and recognitions, including from NASSCOM, Karnataka Government, and Google for Startups Accelerator, and have participated in major industry events, demonstrating traction and industry validation.